Investing
Proceeds from maturities of short-term investments
Pfizer Proceeds from maturities of short-term investments decreased by 3.1% to $4.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $3.96B to $4.58B. Over 4 years (FY 2021 to FY 2025), Proceeds from maturities of short-term investments shows a downward trend with a -10.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher inflows suggest the company is converting its short-term investments back into cash, potentially to fund operations or capital expenditures.
Detailed definition
Cash inflows resulting from the maturity, sale, or collection of short-term investments and marketable securities. This...
Peer comparison
Standard treasury management metric reflecting liquidity cycles.
Metric ID:
investing_proceeds_from_sale_maturity_and_collection_of__91c366Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.11B | $8.28B | $11.60B | $13.42B | $6.73B | $14.94B | $9.73B | $6.40B | $6.19B | $5.42B | $21.25B | $658.00M | $1.05B | $918.00M | $1.50B | $3.96B | $6.55B | $2.74B | $4.72B | $4.58B |
| QoQ Change | — | +293.0% | +40.0% | +15.7% | -49.9% | +121.9% | -34.8% | -34.3% | -3.2% | -12.4% | +291.7% | -96.9% | +60.2% | -12.9% | +63.2% | +164.0% | +65.5% | -58.2% | +72.6% | -3.1% |
| YoY Change | — | — | — | — | +219.4% | +80.4% | -16.1% | -52.3% | -8.0% | -63.7% | +118.3% | -89.7% | -83.0% | -83.1% | -92.9% | +501.1% | +521.0% | +198.0% | +215.3% | +15.7% |
Range$658.00M – $21.25B
CAGR+17.7%
Avg YoY Growth+86.3%
Median YoY Growth+3.9%
Proceeds from maturities of short-term investments at Other Companies
Frequently Asked Questions
- What is Pfizer's proceeds from maturities of short-term investments?
- Pfizer (PFE) reported proceeds from maturities of short-term investments of $4.58B in Q1 2026.
- How has Pfizer's proceeds from maturities of short-term investments changed year-over-year?
- Pfizer's proceeds from maturities of short-term investments increased by 15.7% year-over-year, from $3.96B to $4.58B.
- What is the long-term trend for Pfizer's proceeds from maturities of short-term investments?
- Over 4 years (2021 to 2025), Pfizer's proceeds from maturities of short-term investments has grown at a -10.1% compound annual growth rate (CAGR), from $27.45B to $17.96B.
- What does proceeds from maturities of short-term investments mean?
- Cash received from the maturity or sale of short-term investments.